Ongoing phase III trials of semaglutide for Alzheimer’s disease (EVOKE/EVOKE+) will offer further insights into whether newer GLP-1 medicines may protect against Alzheimer’s disease. This evidence concerns the gene GCG and early-onset autosomal dominant Alzheimer disease.